Get started
PFIZER INC. DL-,05PFIZER INC. DL-,05PFIZER INC. DL-,05

PFIZER INC. DL-,05

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

PFE - our Long Call materializesOur recent recommended top pick from Healthcare sector: PFE: released better than expected financial results; raised full year guidance; The company’s earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion. Pfizer reported adjusted research and development expenses of $2.67 billion for the period, compared to the estimated $2.83 billion. Looking forward, the pharmaceutical giant now projects FY2024 EPS of $2.45 to $2.65, up from the previous guidance of $2.15 to $2.35, and above the consensus estimate of $2.38.
NYSE:PFELong
by IrinaTK
price levels to trade PFE after its earningCertainly! **Pfizer** has been actively advancing its gene therapy pipeline, particularly in the field of hemophilia. Here are some key developments: 1. **Giroctocogene fitelparvovec**: - Pfizer announced positive topline results from the **Phase 3 AFFINE study** evaluating giroctocogene fitelparvovec. This investigational gene therapy targets **hemophilia A** in adults with moderately severe to severe forms of the condition. - Key findings: - Achieved its primary objective of **non-inferiority** and **superiority** compared to routine Factor VIII (FVIII) replacement prophylaxis treatment. - Demonstrated a statistically significant reduction in mean total annualized bleeding rate (ABR) compared to the pre-infusion period. - Most participants maintained FVIII activity >5% at 15 months post-infusion. - Generally well-tolerated, with no impact on efficacy and safety results¹. - Notably, Pfizer also received FDA approval for **Beqvez**, a gene therapy for **hemophilia B**. - Additionally, regulatory submissions for **marstacimab** as a potential treatment for both hemophilia A and B are underway in the U.S. and Europe². 2. **Other Gene Therapy Programs**: - Pfizer currently has three Phase 3 programs investigating gene therapy in populations with high unmet needs: - **Hemophilia B** - **Hemophilia A** - **Duchenne muscular dystrophy**³. Pfizer's commitment to advancing gene therapies holds great promise for patients worldwide. 🌟🧬⁴⁵ 🚀 Source: Conversation with Copilot, 7/30/2024 (1) Pfizer Announces Positive Topline Results From Phase 3 Study of .... www.pfizer.com (2) Pfizer Hemophilia Gene Therapy Meets Phase 3 Goals, But Its Success .... medcitynews.com (3) Pfizer Announces Positive Top-Line Results from Phase 3 Study of .... www.pfizer.com (4) Pfizer Pipeline. cdn.pfizer.com (5) New Drug Development Pipeline: Pfizer's Medicine, Vaccine Discovery .... www.pfizer.com
NYSE:PFELong
by KhanhC.Hoang
Pfizer (PFE) AnalysisOverview:** Pfizer Inc. (PFE) has been in a prolonged downtrend but is showing signs of potential recovery. The recent chart indicates a bounce from the lows, with key technical indicators suggesting a possible reversal. **Technical Analysis:** 1. **Fibonacci Retracement Levels**: - The chart shows Fibonacci retracement levels drawn from the recent high to the low. The stock has rebounded from the lower levels and is currently testing the 23.6% retracement level around $29.50. A sustained break above this level could target the next resistance levels at $32 and $35. 2. **Moving Averages**: - The stock has moved above the short-term moving averages (indicated by the green and blue lines), which suggests bullish momentum. If it can maintain above these levels, it could attract more buying interest. 3. **MACD and RSI**: - The MACD indicator shows a bullish crossover, and the histogram has turned positive, indicating increasing bullish momentum. - The RSI is rising from oversold territory, currently at 87.03, which suggests strong buying pressure but also warrants caution as it nears overbought levels. **Fundamental Perspective:** - **Recent Developments**: Pfizer's ongoing developments in its drug pipeline, including advancements in COVID-19 treatments and vaccines, continue to provide long-term growth potential. Investors should keep an eye on upcoming earnings reports and updates on key products. - **Valuation** The current price level may represent a value opportunity given Pfizer's strong balance sheet and consistent dividend payments. The company has a history of generating significant free cash flow, which supports its ability to invest in new research and return capital to shareholders. **Conclusion:** Pfizer appears to be at a crucial juncture, with technical indicators suggesting a potential trend reversal. Investors should monitor the $29.50 level for a possible breakout and consider the broader market conditions and Pfizer’s upcoming announcements for further confirmation of the bullish trend. **Risk Management:** - Set stop-loss orders below recent lows to manage downside risk. - Consider scaling into the position to mitigate the impact of volatility. **Disclaimer**: This analysis is for informational purposes only and should not be considered as financial advice. Dr SAUD
NYSE:PFELong
by DrSaud1
Pfizer: This sell off is nowhere near finished Pfizer has been getting pushed like crazy on CNBC by fund managers like Josh Brown as a good buy and after looking at the charts above its very easy to see why. Wallstreet pricks like Brown are trying to offload their last remaining shares on unsuspecting retail buyers. As you can see in the first chart on the daily timeframe, Pfizer is below the 200 and tried 3 different times to get above it and failed. In the second chart on the monthly timeframe, Pfizer is now below the 200 on the Monthly and is now consolidating, the last time this happened was back in 2009 and after consolidating below the 200 for 3 months, it tanked 50% for 15 months in a row, from $22.50 down to just under $13 a share. Pfizer will not be a buy for a long long time NYSE:PFE
NYSE:PFEShort
by bradc1984
3
peeking $PFE's levels to manage my positionPfizer Inc. is the best gene therapy stock to buy now. Pfizer expects an FDA decision for Marstacimab, a potential once-weekly subcutaneous treatment for hemophilia B. They also started a Phase 3 study for osivelotor in sickle cell disease. New Product Approvals: Pfizer’s recent product approvals include Abrysvo RSV vaccine, Velsipity (etrasimod) for ulcerative colitis, Penbraya pentavalent meningococcal vaccine, Zavzpret nasal spray for migraine, Litfulo (ritlecitinib) for severe alopecia areata, and Beqvez (fidanacogene elaparvovec), a one-time gene therapy for hemophilia B.
NYSE:PFELong
by KhanhC.Hoang
Pfizer !!! low risk , 20% Gain till next month ?? Hello everyone, today I want to discuss Pfizer's stock which experienced a 58% correction from its peak price and is currently trading around $26. I believe this stock has a lot of potential for both scalpers and long-term investors. With a dividend yield of 6.65% at this price, it's an attractive investment option. Additionally, the earnings report due this week could boost the stock price to $30 by next month. You can refer to the chart for trade stop and stop-loss points. Disclaimer: This information or service is for informational purposes only and is not intended to be personal financial advice #pfizer
NYSE:PFELong
by S_INV28
1
Trade Like A Sniper - Episode 16 - Pfizer - (5th June 2024)This video is part of a video series where I backtest a specific asset using the TradingView Replay function, and perform a top-down analysis using ICT's Concepts in order to frame ONE high-probability setup. I choose a random point of time to replay, and begin to work my way down the timeframes. Trading like a sniper is not about entries with no drawdown. It is about careful planning, discipline, and taking your shot at the right time in the best of conditions. A couple of things to note: - I cannot see news events. - I cannot change timeframes without affecting my bias due to higher-timeframe candles revealing its entire range. - I cannot go to a very low timeframe due to the limit in amount of replayed candlesticks In this session I will be analyzing PFE (Pfizer), starting from the 4-Month chart. - R2F
NYSE:PFE
by Road_2_Funded
Analysis of PFE Price: Is the Stock Undervalued?Analysis of PFE Price: Is the Stock Undervalued? Yesterday, the price of Pfizer's stock rose by more than 2.2%, while the S&P 500 index remained almost unchanged from the opening to the closing of trading. This fact is noteworthy, considering that for many months the price of PFE stock performed worse than the market - if the S&P 500 grew by 23% during 2023, then the price of PFE decreased by approximately 43%. The decline in 2023 (shown by the red channel) was disappointing. But what about now - is the situation changing? Are investors missing out on something important by turning away from PFE? Several factors indicate that PFE stock may have optimistic prospects. Fundamentally - Investors Place has included PFE in the list of the most undervalued stocks for reasons such as: → 2023 saw a record number of FDA approvals. New drugs could boost sales. → Pfizer acquired Seagen, significantly expanding its capabilities in cancer research. This supports the company's strategy to become a world-class leader in oncology. → By 2030, Pfizer plans to release 8 drugs that could become "blockbusters." From a technical analysis perspective of the daily chart of PFE: → Attention is drawn to the 3 candles from December 13-15, 2023 - on each of these days, over 100 million shares were traded on the NYSE, which is unusually high for this market. Large investors may have been building long positions - as the price of PFE rose out of the zone marked by the 3 candles in purple. → Throughout 2024, the price attempted to drop below the indicated zone, but each time it did not make progress. → The decline on April 25 looks like a Final Shakeout pattern in Richard Wyckoff's terminology, indicating the completion of the stock accumulation process. The price action in May 2024 looks extremely bullish: → PFE stock is outperforming the market. → The RSI indicator remains above the level of 50. → The downtrend has been broken. According to TipRanks, the average forecasted price of PFE stock by Wall Street analysts is $33.15 (+13.10% from current levels). Buy and sell stocks of the world's biggest publicly-listed companies with CFDs on FXOpen’s trading platform. Open your FXOpen account now or learn more about trading share CFDs with FXOpen. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:PFE
by FXOpen
2